These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 39390475)
1. Clinical evaluation of oxaliplatin-loaded drug-eluting callispheres beads transarterial chemoembolization for unresectable or recurrent esophageal carcinoma. Bi Y; Ren J; Han X World J Surg Oncol; 2024 Oct; 22(1):272. PubMed ID: 39390475 [TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma. Bi Y; Shi X; Ren J; Yi M; Han X; Song M BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608 [TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer. Bi Y; Li F; Ren J; Han X Front Pharmacol; 2022; 13():1079707. PubMed ID: 36518678 [No Abstract] [Full Text] [Related]
4. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. Bi Y; Ren K; Ren J; Ma J; Han X Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827 [No Abstract] [Full Text] [Related]
5. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads. Bi Y; Shi X; Ren J; Yi M; Han X Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365 [TBL] [Abstract][Full Text] [Related]
6. Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III-IV lung cancer. Bi Y; Shi X; Yi M; Han X; Ren J Acta Radiol; 2022 Mar; 63(3):311-318. PubMed ID: 33615822 [TBL] [Abstract][Full Text] [Related]
7. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. Wu B; Zhou J; Ling G; Zhu D; Long Q World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773 [TBL] [Abstract][Full Text] [Related]
8. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis. Bi Y; Jiao D; Wang Y; Han X; Ren J World J Surg Oncol; 2022 Jul; 20(1):229. PubMed ID: 35821043 [TBL] [Abstract][Full Text] [Related]
9. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients. Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of raltitrexed-eluting CalliSpheres Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379 [TBL] [Abstract][Full Text] [Related]
11. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma. Li J; Wang N; Shi C; Liu Q; Song J; Ye X J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307 [TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer. Bi Y; Shi X; Ren J; Yi M; Han X; Song M Abdom Radiol (NY); 2021 Jun; 46(6):2833-2838. PubMed ID: 33386908 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer. Bie Z; Li Y; Li B; Wang D; Li L; Li X Thorac Cancer; 2019 Sep; 10(9):1770-1778. PubMed ID: 31321919 [TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. Bi Y; Jiao D; Ren J; Han X Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of gemcitabine-loaded callispheres drug-eluting beads for patients with advanced and inoperable lung cancer: A case series study. Bi Y; Zhang B; Ren J; Han X; Wu W Front Pharmacol; 2022; 13():992526. PubMed ID: 36249775 [No Abstract] [Full Text] [Related]
16. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis. Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460 [TBL] [Abstract][Full Text] [Related]
17. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680 [No Abstract] [Full Text] [Related]
18. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530 [TBL] [Abstract][Full Text] [Related]
19. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma. Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients. Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]